EMEA-000371-PIP01-08

Key facts

Invented name
Revlimid
Active substance
lenalidomide
Therapeutic area
Oncology
Decision number
P/102/2008
PIP number
EMEA-000371-PIP01-08
Pharmaceutical form(s)
Capsule, hard
Condition(s) / indication(s)
Myelodysplastic Syndrome
Route(s) of administration
Oral use
Contact for public enquiries
Celgene Europe Limited

E-mail: medinfo.intl@celgene.com
Country: Switzerland
Phone: +41 327298500
Fax: +41 327298508

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Related content

Topics

How useful was this page?

Add your rating